Articles by Philip Ward - Applied Clinical Trials

ADVERTISEMENT

Articles by Philip Ward

Philip Ward


Philip Ward is ACT's European editor, phone +44 1244 538583, philipward1@btconnect.com

Articles
Experimental Ebola Drugs Must be Tested Ethically, Experts Urge
August 22, 2014

Researchers and health authorities need to ensure that experimental drugs to treat Ebola are distributed fairly...

ICR Reveals New Courses on EU Regulation & Line Management
August 7, 2014

ICR has announced two new courses for December 2014 about the impact of the European Union regulation and essential line management.

ACRES and Fujitsu Unveil New Partnership Deal
August 6, 2014

Fujitsu and ACRES have linked up to address challenges facing the development of medicines and health-related research endeavors.

EFGCP Warns About Risks of Overprotecting Data
August 1, 2014

The European Forum for Good Clinical Practice says proposed restrictive access to clinical data would impede further progress in health research.

Synexus Expands in Germany with New Center in Bochum
July 31, 2014

Synexus has opened a research center in Bochum.

ESMO Voices Deep Concern About Future of Cancer Research
July 25, 2014

ESMO is concerned that the proposed European Union General Data Protection Regulation could make cancer research impossible and add a significant burden to both doctors and cancer patients.

EMA Issues Robust Response to Conflict of Interest Claims
July 17, 2014

EMA has insisted that the concerns raised about its scientific advice given to pharmaceutical companies stem from a flawed understanding of the activities of the agency and its partners in this area.

Is it Time to Lock up those who Commit Research Fraud?
July 16, 2014

Two experts have engaged in a lively debate about whether research fraud should be classed as a criminal act.

EFPIA Unveils Action Plan for Lithuania
July 10, 2014

The Lithuanian Ministry of Health and EFPIA have announced a new Joint Working Agreement.

Advertisement

ADVERTISEMENT

Untitled Document
Click here